MSD is pushing to enter the HIV treatment market in Korea.

Industry sources have reported that MSD Korea’s once-daily fixed-dose HIV combination tablet ‘Delstrigo (doravirine/lamivudine/tenofovir)’ will be reviewed by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee (DREC) meeting held in June next month.

Considering that the company applied for Delstrigo's reimbursement listing in January, its listing process is proceeding relatively smoothly.

MSD Korea had applied for the reimbursement of Delstrigo for its 'treating HIV-1 infection in adult patients with no prior antiretroviral treatment experience’ indication.